Guillain-Barré Syndrome(GBS)
Definition &CausesSymptomsInvestigations & TreatmentsRisk Factors & PreventionOutcome
Definition and Causes:


A neurological disorder that results when the body's immune system (defence mechanism) attacks the nerves of the body. The disease presents with varying degree of weakness and tingling sensation of the limbs. The symptoms may increase to the intensity until certain muscles cannot be used at all and results in paralysis. In some cases it can be life threatening when interfere with muscles used for breathing; and may cause respiratory failure.


GBS affects men and women of all ethnicities and ages. Treatment is available for the condition and in most cases, people recover fully.



The exact cause of this disorder is unknown. All we know it is a very rare disorder. Sometimes it is suggested; infections of GI tract and respiratory system by certain bacteria and viruses; may often be associated with this condition and usually precedes the disorder.


People with lymphoma, HIV, or lupus seem to be more at higher risk for developing GBS.


Back to Top


Start with tingling and sensation of numbness in the limbs, usually in an ascending manner; meaning from periphery of the body towards the center or torso. The hands, feet, and face may be affected first in some patients.


The symptoms usually develop over few days; reaching to its worst at about 2 weeks after onset.


Other symptoms include:

  • Leg, arm, and facial muscle weakness
  • Weakness involving speech and swallowing muscle
  • Back pain
  • Breathing may be compromised in case of respiratory muscle weakness
  • Decreased ability to move the eyes


In severe cases, profound weakness, respiratory difficulties, or unstable blood pressure may develop, requiring admission to a hospital or an intensive care unit and possibly assistance from a breathing machine called a ventilator.


A person experiencing a mild case of GBS may only have slight weakness or numbness and may not require hospitalization or treatment.


Back to Top
Investigations and Treatment:


History: The family doctor will inquire about:

  • History of recent viral or bacterial infections
  • History of vaccination
  • Past medical history


Physical exam might include:

  • A full physical and neurological examination will be conducted, by the family doctor, to determine the extent of muscle weakness



  • Blood tests may be performed to diagnose, and the antibodies may be tested


Nerve conductions velocity (NCV):

  • It is done to measure the electrical activity along the nerve to evaluate the disruption; by using small electrodes placed on the skin, to measure the speed and strength of the nerve


Lumbar puncture (spinal tap):

  • It is a procedure to determine elevated protein with normal cell count in the cerebrospinal fluid (CSF); involves inserting a needle between the two spines of the back bone in the lower back and taking the sample of the fluid, which bathes the spinal cord and the brain protecting the brain matter from the injury infections etc.


Forced vital capacity:

  • Used to monitor respiratory status and assist with decision to intubate to facilitate breathing artificially by machines




For those presenting with mild to moderate weakness without respiratory impairment → early recognition, diagnosis and treatment is commenced in lue of fast recovery.


In severe cases the recovery can take longer, requiring emergent medical attention requiring assessment of vitals along with evaluation of respiratory status.


Severe cases may require intubation and mechanical ventilation.


Treatment options include:

  • Plasmapheresis
  • Intravenous immunoglobulin (IVIg) therapy


Plasmapheresis helps remove antibodies from the blood. Antibodies are a part of the immune system and normally help your body fight inflammation and infection. With conditions like GBS, certain antibodies damage nerves and cause a loss of transmission of electrical signals to the muscles. Plasmapheresis works by separating a person's blood into its two main components: cells and plasma. The cells are returned to the body. The plasma is discarded and replaced with artificial plasma. Plasmapheresis works best for people with GBS when started within the first 2 weeks of symptom onset.


Intravenous immunoglobulin (IVIg): It is still unknown how it works; but it is a collection of antibodies from donated blood.



Blood product derivative



Copyright © 2013 Innovate R&D


Back to Top
Risk Factors and Prevention:


Vaccination against the flu may trigger the disease in a very small number of people.


A person's risk of developing GBS after a flu shot is about one in one million. Keep in mind that receiving the flu shot helps protect your own health and that of those around you and is recommended despite the extremely small increased risk of GBS.


Back to Top
  • Can be a very distressing disorder because of its sudden and unexpected onset
  • Most people reach the stage of greatest weakness within the first 2 weeks after symptoms appear, and by the third week of the illness 90 percent of all patients are at their weakest
  • The recovery period may be as little as a few weeks or as long as a few years
  • About 30 percent of those with Guillain-Barré still have a residual weakness after 3 years
  • About 3 percent may suffer a relapse of muscle weakness and tingling sensations many years after the initial attack


Back to Top
Copyright © 2011-2019 Innovate R&D

educate Are you a Healthcare professional or patient?

Healthcare Professionals would include: Physicians (MD,OD), Physician assistants, Nurses, Pharmacists,Allied Health Workers (PT, OT, SLP, etc), Chiropractors, Paramedics, Optometrists, Dentists, Podiatrists etc, and students within these disciplines.

educate ** You are required to register **

eDucate is committed to optimizing the delivery of health information across the Healthcare continuum. To this end eDucate uses a wide array of learning tools, including Webinars, Quick Review Charts, Graphs, Brochures, Videos and Slide Presentations.

Professional Membership Benefits include free access to all archived and upcoming Webinars:

educate DISCLAIMER: This website is owned and operated by The Innovate Research and Development LP (Innovate R&D). All references herein to Innovate R&D shall be deemed to include any subsidiary, affiliate, associate or successor corporation of Innovate R&D. By entering and using this site, you agree to the "Terms of Use"for this website. If you do not agree to these terms and conditions then exit from this site immediately. Although Innovate R&D updates this website regularly with material believed to be accurate at the time of posting, Innovate R&D does not guarantee the accuracy, completeness, timeliness or currency of the material and consequently Innovate R&D expressly disclaims any liability for errors or omissions in the material contained in the website. The Innovate R&D website and all contents are provided as-is, and all representations and warranties, express or implied, relating to the website or the content are disclaimed, including any implied warranty of merchantability, fitness for a particular purpose or non-infringement, as well as any warranty of quality, functionality, accuracy, currency, completeness, reliability, operability, use performance or absence of viruses. In no way or event will Innovate R&D or any party that has been involved in the creation, production, promotion and marketing be liable to you or any other party for perceived direct or indirect damages. You assume all responsibility and risk of loss resulting from the use of our website.